Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Wellington Management in the transaction. Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Reshape Biotech in the transaction. Reshape Biotech, a robotic technology developer, announced it raised its $20 million in...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Solu Therapeutics in the transaction. Solu Therapeutics announced the closing of an oversubscribed $31 million seed financing co-led...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised Photys Therapeutics on the deal. Photys Therapeutics, a developer of phosphorylation-inducing chimeric small molecule (PHICS) medicines, announced its $75 million Series A financing...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Carbon Biosciences on the deal. Carbon Biosciences, a developer of novel parvovirus-derived gene therapies, announced its emergence from stealth mode and the closing of...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Seismic Therapeutic, Inc. on the deal while Gunderson Dettmer represented Lightspeed Venture Partners. Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised HotSpot Therapeutics on the deal. HotSpot Therapeutics Inc., a biotechnology company, announced a strategic collaboration agreement with Caris Life...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Theseus Pharmaceuticals on the deal. Theseus Pharmaceuticals, Inc., a biopharmaceutical company focused on improving the lives of cancer...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Immunitas Therapeutics on the deal. Immunitas Therapeutics, an immuno-oncology biotech company, announced its $58 million Series B financing round. The round...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Boston Pharma on the deal. Boston Pharma, a clinical stage biopharmaceutical company developing differentiated therapeutics, announced its strategic...
You must be a Standard 1 Year member to access this content.
